Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bitdeer Technologies Group (BTDR) vs 10X Genomics Inc (TXG) Price & Performance

Bitdeer Technologies GroupTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Bitdeer Technologies Group vs 10X Genomics Inc — how do they compare? Bitdeer Technologies Group trades at $12.5 (market cap $3.01B), while 10X Genomics Inc trades at $45.9 (market cap $5.81B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.

BTDRTXG
Market Cap
$3.01B$5.81B
Sector
TechnologyHealth
52-Week High
$25.90$45.80
52-Week Low
$7.28$11.34
Enterprise Value
$4.77B$5.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bitdeer Technologies Group

BTDR trades at $12.13, down 8.73% over 24 hours, with technical indicators signaling a bearish trend. The stock shows strong analyst support with 9 out of 11 ratings as Buy and a consensus price target of $23.40, but fundamentals reveal challenges: negative net income margin of -26.96% and three consecutive quarterly earnings misses. Recent news highlights expansion into AI infrastructure, including a new $36 million manufacturing facility in Nevada and an AI cloud platform award in June 2026.

The outlook is mixed: bullish analyst sentiment and strategic growth in AI and mining infrastructure offer upside potential, but persistent losses, negative cash flow from operations, and high debt-to-asset ratio of 35.69% pose significant risks. Investors should weigh the company's expansion against its financial health and sector volatility.

10X Genomics Inc

TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.

The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.

Read more on BTDR

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG